Dechra launches new canine atopic dermatitis therapy

Dechra has announced the UK launch of Sporimune, a new treatment to tackle atopic dermatitis in dogs, as part of its expanding range of canine dermatological therapies.

This easy-dispensing, flexible-dosing ciclosporin-based product is licensed for the treatment of chronic manifestations of the disease, which is incurable but can be managed using a multimodal approach.

It is being introduced to veterinary professionals as part of Dechra's Partners in Practice programme, which aims to support vets and vet nurses in diagnosing, controlling and maintaining complex dermatological conditions.

Around 20 percent of all small animal consultations involve skin conditions, with canine atopic dermatitis being particularly challenging to diagnose and manage effectively.

Roger Brown, senior brand manager at Dechra Veterinary Products, said: "We have also developed support materials around the use of Sporimune for practices, including client information leaflets and a video on how to use the dosing syringe."

This comes after the firm introduced a new equine navicular syndrome therapy, Osphos, in September 2014.